Packaging and 0.8ml prefilled syringe of Humira (Adalimumab), a biologic medication for the treatment of rheumatoid and psoriatic arthritis, autoimmune diseases. Humira is a human monoclonal antibody which targets excess tumor necrosis factor, a protein capable of destroying cancer cells, in the joint fluid. Overproduction of tumor necrosis factor causes inflammation, swelling, and pain. Humira was approved for use by the FDA in 2003.
Model release not required. Property release not required.